The effect of AlloDerm on the initiation and growth of human neovessels

Authors

  • Sean R. Weiss MD,

    1. Department of Otorhinolaryngology–Head and Neck Surgery, Louisiana State University Health Sciences Center, New Orleans, Louisiana, U.S.A.
    Search for more papers by this author
  • Justin M. Tenney MD,

    Corresponding author
    1. Department of Otorhinolaryngology–Head and Neck Surgery, Louisiana State University Health Sciences Center, New Orleans, Louisiana, U.S.A.
    • Louisiana State University Health Sciences Center, Department of Otolaryngology–Head and Neck Surgery, 533 Bolivar Street, New Orleans, LA 70112
    Search for more papers by this author
  • Jessica L. Thomson PhD,

    1. U. S. Department of Agriculture, Agricultural Research Service, Southern Regional Research Center, Baton Rouge, Louisiana, U.S.A.
    Search for more papers by this author
  • Catherine T. Anthony PhD,

    1. Department of Surgery, Louisiana State University Health Sciences Center, New Orleans, Louisiana, U.S.A.
    Search for more papers by this author
  • Ernest S. Chiu MD,

    1. Department of Surgery, Louisiana State University Health Sciences Center, New Orleans, Louisiana, U.S.A.
    Search for more papers by this author
  • Paul L. Friedlander MD,

    1. Department of Otolaryngology, Tulane University Health Sciences Center, New Orleans, Louisiana, U.S.A.
    Search for more papers by this author
  • Eugene A. Woltering MD

    1. Department of Surgery, Louisiana State University Health Sciences Center, New Orleans, Louisiana, U.S.A.
    Search for more papers by this author

  • Presented at the American Head and Neck Society Annual Meeting and Research Workshop on the Biology, Prevention, and Treatment of Head and Neck Cancer, Chicago, Illinois, U.S.A., August 17–20, 2006.

Abstract

Objectives/Hypothesis:

AlloDerm (LifeCell Corp., Branchburg, NJ) is commonly employed for reconstruction of ablative soft tissue and mucosal defects following surgical resections. Although devoid of growth factors, AlloDerm may serve as an adhesive matrix for binding of growth factors, increasing local angiogenesis, and wound healing. We hypothesized that AlloDerm would enhance angiogenesis and might be altered with autologous blood products to enhance initiation of the angiogenic response.

Methods:

We used a human placental vein in a fibrin-thrombin clot-based angiogenesis model. Four groups, human placental vein (HPVM), HPVM with AlloDerm, HPVM with AlloDerm plus platelet-poor plasma, and HPVM with AlloDerm plus platelet-rich plasma were evaluated. Endothelial cell growth was evaluated visually (40×). Hematoxylin and eosin staining and immunofluorescent staining for growth within the AlloDerm matrix were also performed. To assess human umbilical vein endothelial cell (HUVEC) sites of attachment to AlloDerm, we incubated HUVEC cells with AlloDerm for a period of 2 weeks and evaluated attachment with anti-factor VIII immunofluorescence.

Results:

Angiogenic initiation decreased in the combined placental vein with AlloDerm group (P < .0001 at day 7, 14, 21). Additionally, initiation in the AlloDerm plus platelet-poor plasma group was significantly better than the AlloDerm alone group when placentas 2 and 3 were compared (P < .0001). On hematoxylin and eosin staining and immunofluorescent factor VIII staining, no endothelial growth into the AlloDerm was noted in the samples analyzed.

Conclusions:

AlloDerm may be enriched with platelet-poor plasma to stimulate greater initiation and wound healing; however, AlloDerm inhibits angiogenic initiation in this model. Laryngoscope, 2010

Ancillary